


Express Mail Label No.: EV 058119255 US

Date of Deposit: November 18, 2002

PATENT APPLICATION

Attorney Docket No. 15966-557 (Cura-57)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Shimkets and Prayaga

SERIAL NUMBER : 09/494,585

EXAMINER : Christine Saoud

FILING DATE : January 31, 2000

ART UNIT : 1647

FOR : NOVEL FIBROBLAST GROWTH FACTOR AND NUCLEIC ACIDS ENCODING SAME

Box AF

Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Transmitted herewith in response to the September 17, 2002, Office Action in the present application are the following documents:

Response to Final Office Action, including Exhibit 1 (27 pp.);

Return Postcard.

No fee is believed due at this time. The Commissioner is hereby authorized to charge payment of any filing fees required in connection with the papers transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 15966-557). A duplicate copy of this transmittal letter is enclosed.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Kristin E. Konzak, Reg. No. 44,848

Attorney/Agent for Applicants

c/o MINTZ, LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel: (617) 542-6000

Dated: November 18, 2002

Please address all correspondence to customer number 30623.



30623

PATENT TRADEMARK OFFICE

Express Mail Label No.: EV 058119255 US  
Date of Deposit: November 18, 2002

PATENT APPLICATION  
Attorney Docket No. 15966-557 (Cura-57)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Shimkets and Prayaga  
SERIAL NUMBER : 09/494,585  
FILING DATE : January 31, 2000  
FOR : NOVEL FIBROBLAST GROWTH FACTOR AND NUCLEIC ACIDS ENCODING SAME

EXAMINER : Christine Saoud  
ART UNIT : 1647

Box AF  
Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

NOV 20 2002

AMENDMENT AND RESPONSE

TECH CENTER 1600/2900

This filing is in response to the September 17, 2002, Final Office Action ("Office Action"). These documents are due on or before Monday, November 18, 2002, to trigger an expedited Advisory Action. Please enter the following amendments and consider the remarks prior to further prosecution.

**In the Specification:**

Replace the Abstract on page 81 with the following amended Abstract.

-- The present invention provides FGF-CX polypeptides and polynucleotides, and antibodies that immunospecifically bind to FGF-CX or any derivative, variant, mutant, or fragment of the FGF-CX polypeptide, polynucleotide or antibody. The invention additionally provides methods of use for a FGF-CX polypeptide, polynucleotide and antibody. --

Replace page 81 with substitute page 81 attached in Appendix A.

*Pursuant to 37 CFR 1.121(b), a marked up version of the Abstract showing the changes made appears as Appendix B of this Amendment. A substitute page 81 is provided in Appendix A.*

**In the Claims:**

Replace pending claims 1, 2, 4, 5, 14, 19 and 28 with the following:

1. (Twice Amended) An isolated nucleic acid molecule encoding a polypeptide comprising a sequence of SEQ ID NO:2, or the complement of said nucleic acid molecule.